Int J Med Sci
2014; 11(7):680-684.
doi:10.7150/ijms.8916 This issueCite
Research Paper
New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial Fibrillation
Josep M. Alegret1✉, Xavier Viñolas2, Miguel A. Arias3, Antoni Martínez-Rubio4, Pablo Rebollo5, Carles Ràfols6, José L. Martínez-Sande7
1. Grup de Recerca Cardiovascular, Hospital Universitari de Sant Joan, IISPV, Universitat Rovira i Virgili, Reus, Spain. 2. Hospital de la Sta. Creu i St. Pau, Barcelona, Spain. 3. Hospital Virgen de la Salud, Toledo, Spain. 4. Hospital Universitari Parc Taulí, Sabadell, Spain. 5. LA-SER Outcomes, Oviedo, Spain. 6. Medical Department, Bayer HealthCare, Barcelona, Spain. 7. Hospital Clínico, Santiago de Compostela, Spain.
✉ Corresponding author: Josep M Alegret, Grup de Recerca Cardiovascular, Hospital Universitari de Sant Joan, Departament de Medicina i Cirurgia, Universitat Rovira i Virgili. c/ Dr Josep Laporte, nº1, 43204 Reus. Email: josepmaria.alegretnet.More
Citation:
Alegret JM, Viñolas X, Arias MA, Martínez-Rubio A, Rebollo P, Ràfols C, Martínez-Sande JL. New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial Fibrillation. Int J Med Sci 2014; 11(7):680-684. doi:10.7150/ijms.8916. https://www.medsci.org/v11p0680.htm
New oral anticoagulants (NOAC) have demonstrated their efficacy as an alternative to vitamin K antagonists (VKA) in the prophylaxis of cardioembolic events in patients with atrial fibrillation (AF). However, evidence on the benefits of NOAC in health-related quality of life (HRQoL) is lacking.We evaluated changes in HRQoL related to oral anticoagulation therapy employing a specific questionnaire in a cohort of 416 patients with AF undergoing electrical cardioversion. In terms of HRQoL, we observed a progressive adaptation to treatment with VKA; satisfaction with NOAC remained constant. Older age, higher left ventricular ejection fraction and NOAC were associated with better HRQoL.
Keywords: vitamin K antagonists, dabigatran, health-related quality of life, new oral anticoagulants, ribaroxaban.
Citation styles
APA
Alegret, J.M., Viñolas, X., Arias, M.A., Martínez-Rubio, A., Rebollo, P., Ràfols, C., Martínez-Sande, J.L. (2014). New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial Fibrillation. International Journal of Medical Sciences, 11(7), 680-684. https://doi.org/10.7150/ijms.8916.
ACS
Alegret, J.M.; Viñolas, X.; Arias, M.A.; Martínez-Rubio, A.; Rebollo, P.; Ràfols, C.; Martínez-Sande, J.L. New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial Fibrillation. Int. J. Med. Sci. 2014, 11 (7), 680-684. DOI: 10.7150/ijms.8916.
NLM
Alegret JM, Viñolas X, Arias MA, Martínez-Rubio A, Rebollo P, Ràfols C, Martínez-Sande JL. New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial Fibrillation. Int J Med Sci 2014; 11(7):680-684. doi:10.7150/ijms.8916. https://www.medsci.org/v11p0680.htm
CSE
Alegret JM, Viñolas X, Arias MA, Martínez-Rubio A, Rebollo P, Ràfols C, Martínez-Sande JL. 2014. New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial Fibrillation. Int J Med Sci. 11(7):680-684.